DKDaniel Kaemmerer

Daniel Kaemmerer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Kaemmerer has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Duodenale neuroendokrine Neoplasien (NEN): Update endoskopische und chirurgische Therapie

    by Daniel Kämmerer

    Duodenal neuroendocrine neoplasms (d-NEN) are rare neoplasms accounting for approximately 3% of all neuroendocrine neoplasms. They are classified into well-differentiated neoplasms (G1-G3), poorly differentiated neuroendocrine carcinomas (NEC) and mixed tumors; the majority of these tumors are nonfunctional. Some neoplasms are associated with genetic syndromes, such as multiple endocrine neoplasia type 1 or neurofibromatosis type 1. The diagnosis is made using endoscopic, laboratory, cross-sectional and molecular imaging techniques, such as gallium-68-DOTATATE PET/CT. Therapeutically, the tumor size in addition to histopathological findings, is the most important factor: tumors < 5 mm should be removed endoscopically and tumors 5-10 mm in size can also be resected endoscopically after risk assessment. Tumors > 10 mm should generally be treated surgically. An exception is the duodenal nonmetastatic gastrinoma, which should always be resected. The most important surgical interventions are local resections with lymphadenectomy or oncological pancreaticoduodenectomy, particularly for ampullary tumors, which have a higher risk of metastasis. In recent years, increasingly advanced combined surgical endoscopic techniques (rendezvous procedures) have been added to the therapeutic options but due to the oncological value have not yet been incorporated into the guidelines.

  • Anaphylaktischer Schock nach Misteltherapie

    by Daniel Kaemmerer, Merten Hommann

    Zusammenfassung Lebensbedrohliche Nebenwirkungen nach Misteltherapien werden von komplementärmedizinisch arbeitenden Ärzten zumeist negiert. Wir berichten über einen lebensbedrohlichen anaphylaktischen Schock nach erfolgter Misteltherapie. Bei Patienten mit einem Karzinoidsyndrom (Flushes, Diarrhöen, Bronchokonstriktion) bei dem Befund einer neuroendokrinen Neoplasie kann die Diagnose eines anaphylaktischen Schocks maskiert werden. Alle Patienten sollten bei einer geplanten komplementärmedizinischen Misteltherapie auch über seltene lebensbedrohliche Nebenwirkungen aufgeklärt werden.


  • Open Access

    Nuclear Medicine and Surgery on the Way to Personalized Medicine. Ten Years of Clinical and Translational Oncology and Research

    by Daniel Kaemmerer

    Surgery with a complete tumor removal is the only therapeutic option with a curative approach in a neuroendocrine tumor disease. Recurrent abdominal surgery is associated with inflammation, altered anatomy, and scar tissue and can be challenging [1]. Additionally, tumor lesions can be really small, invisible, or not palpable by the surgeon’s fingers. For that reason, an intraoperative diagnostic tool is necessary because the prior imaging (scintigraphy, PET/CT) has a reduced sensitivity with lower tumor size. Sufficient, preoperative, and intraoperative imaging can provide the surgeon with valuable assistance and also significantly simplify the surgical procedure. Depending on the intraoperative findings, the surgical intervention can be expanded or even significantly reduced.

  • Open Access

    Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues

    by Benjamin Wende, Anna-Sophia Liselott Beyer, Niklas Ruhnke, Daniel Kaemmerer, Jörg Sänger, Stefan Schulz, Amelie Lupp

    Little information is available concerning protein expression of the calcitonin receptor-like receptor (CALCRL) at the protein level. Here, we developed a rabbit monoclonal antibody, 8H9L8, which is directed against human CALCRL but cross-reacts with the rat and mouse forms of the receptor. We confirmed antibody specificity via Western blot analyses and immunocytochemistry using the CALCRL-expressing neuroendocrine tumour cell line BON-1 and a CALCRL-specific small interfering RNA (siRNA). We then used the antibody for immunohistochemical analyses of various formalin-fixed, paraffin-embedded specimens of normal and neoplastic tissues. In nearly all tissue specimens examined, CALCRL expression was detected in the capillary endothelium, smooth muscles of the arterioles and arteries, and immune cells. Analyses of normal human, rat, and mouse tissues revealed that CALCRL was primarily present in distinct cell populations in the cerebral cortex; pituitary; dorsal root ganglia; epithelia, muscles, and glands of the larger bronchi; intestinal mucosa (particularly in enteroendocrine cells); intestinal ganglia; exocrine and endocrine pancreas; arteries, capillaries, and glomerular capillary loops in the kidneys; the adrenals; Leydig cells in the testicles; and syncytiotrophoblasts in the placenta. In the neoplastic tissues, CALCRL was predominantly expressed in thyroid carcinomas, parathyroid adenomas, small-cell lung cancers, large-cell neuroendocrine carcinomas of the lung, pancreatic neuroendocrine neoplasms, renal clear-cell carcinomas, pheochromocytomas, lymphomas, and melanomas. In these tumours with strong expression of CALCRL, the receptor may represent a useful target structure for future therapies.


  • Open Access

    Co-Expression of Adaptor Protein FAM159B with Different Markers for Neuroendocrine Cells: An Immunocytochemical and Immunohistochemical Study

    by Anna-Sophia Liselott Beyer, Daniel Kaemmerer, Jörg Sänger, Amelie Lupp

    Little is known about the adaptor protein FAM159B. Recently, FAM159B was shown to be particularly expressed in neuroendocrine cells and tissues, such as pancreatic islets and neuroendocrine cells of the bronchopulmonary and gastrointestinal tracts, as well as in different types of neuroendocrine tumours. To gain insights into possible interactions of FAM159B with other proteins and/or receptors, we analysed the co-expression of FAM159B and various neuroendocrine-specific markers in the cancer cell lines BON-1, PC-3, NCI-h82, OH-1, and A431 and also in human pancreatic tissues and pancreatic neuroendocrine tumours. The markers included prominent markers of neuroendocrine differentiation, such as chromogranin A (CgA), neuron-specific enolase (NSE), synaptophysin (SYP), insulinoma-associated protein 1 (INSM1), neural cell adhesion molecule 1 (NCAM1), serotonin (5-HT), somatostatin-14/28 (SST), and several receptors that are typically expressed by neuroendocrine cells, such as dopamine receptor 2 (D2R), somatostatin receptor (SSTR) 1, 2, 3, 4 and 5, and regulator of G-protein signalling 9 (RGS9). FAM159B was expressed evenly throughout the cytosol in all five cancer cell lines. Immunocytochemical and immunohistochemical analyses revealed co-expression of FAM159B with SYP, INSM1, RGS9, D2R, SSTR2, SSTR3, SSTR4, and SSTR5 and strong overlapping co-localisation with NSE. Double-labelling and co-immunoprecipitation Western blot analyses confirmed a direct association between FAM159B and NSE. These results suggest the involvement of FAM159B in several intracellular signalling pathways and a direct or indirect influence on diverse membrane proteins and receptors.


  • Open Access

    Assessment of G Protein-Coupled Oestrogen Receptor Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody

    by Maria Bubb, Anna-Sophia Lieselott Beyer, Pooja Dasgupta, Daniel Kaemmerer, Jörg Sänger, Katja Evert, Ralph M. Wirtz, Stefan Schulz, Amelie Lupp

    In addition to the classical oestrogen receptors, ERα and ERβ, a G protein-coupled oestrogen receptor (GPER) has been identified that primarily mediates the rapid, non-genomic signalling of oestrogens. Data on GPER expression at the protein level are contradictory; therefore, the present study was conducted to re-evaluate GPER expression by immunohistochemistry to obtain broad GPER expression profiles in human non-neoplastic and neoplastic tissues, especially those not investigated in this respect so far. We developed and thoroughly characterised a novel rabbit monoclonal anti-human GPER antibody, 20H15L21, using Western blot analyses and immunocytochemistry. The antibody was then applied to a large series of formalin-fixed, paraffin-embedded human tissue samples. In normal tissue, GPER was identified in distinct cell populations of the cortex and the anterior pituitary; islets and pancreatic ducts; fundic glands of the stomach; the epithelium of the duodenum and gallbladder; hepatocytes; proximal tubules of the kidney; the adrenal medulla; and syncytiotrophoblasts and decidua cells of the placenta. GPER was also expressed in hepatocellular, pancreatic, renal, and endometrial cancers, pancreatic neuroendocrine tumours, and pheochromocytomas. The novel antibody 20H15L21 will serve as a valuable tool for basic research and the identification of GPER-expressing tumours during histopathological examinations.


  • Open Access

    Immunohistochemical Evaluation of Adaptor Protein FAM159B Expression in Normal and Neoplastic Human Tissues

    by Anna-Sophia Lieselott Beyer, Daniel Kaemmerer, Jörg Sänger, Katja Evert, Amelie Lupp

    FAM159B is a so-called adaptor protein. These proteins are essential components in numerous cell signalling pathways. However, little is known regarding FAM159B expression in normal and neoplastic human tissues. The commercially available rabbit polyclonal anti-human FAM159B antibody HPA011778 was initially characterised for its specificity using Western blot analyses and immunocytochemistry and then applied to a large series of formalin-fixed, paraffin-embedded normal and neoplastic human tissue samples. Confirmation of FAM159B’s predicted size and antibody specificity was achieved in BON-1 cells, a neuroendocrine tumour cell line endogenously expressing FAM159B, using targeted siRNA. Immunocytochemical experiments additionally revealed cytoplasmic expression of the adaptor protein. Immunohistochemical staining detected FAM159B expression in neuronal and neuroendocrine tissues such as the cortex, the trigeminal ganglia, dorsal root and intestinal ganglia, the pancreatic islets and the neuroendocrine cells of the bronchopulmonary and gastrointestinal tract, but also in the syncytiotrophoblasts of the placenta. FAM159B was also expressed in many of the 28 tumour entities investigated, with high levels in medullary and anaplastic thyroid carcinomas, parathyroid adenomas, lung and ovarian carcinomas, lymphomas and neuroendocrine tumours of different origins. The antibody HPA011778 can act as a useful tool for basic research and identifying FAM159B expression in tissue samples.


  • Primary Neuroendocrine Neoplasia of the Liver

    by Daniel Kaemmerer, Almut Kunze, Franz C. Robiller, Merten Hommann, Martin Anlauf

    The presence of primary neuroendocrine tumors in the liver is still a matter of controversy. We present a case of a somatostatin-receptor–positive mass of the liver in the 68Ga-DOTATOC PET/CT. No other primary tumor was found after conventional imaging, endoscopically, and after liver-segment resection. Immunohistochemically, a constellation of findings was found to be compatible with a primary neuroendocrine neoplasm of the liver.

  • Open Access

    Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment

    by Antonia Busse, Liliana H. Mochmann, Christiane Spenke, Ruza Arsenic, Franziska Briest, Korinna Jöhrens, Hedwig Lammert, Bence Sipos, Anja A. Kühl, Ralph Wirtz, et al.

    Checkpoint inhibitors have shown promising results in a variety of tumors; however, in neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), low response rates were reported. We aimed herein to investigate the tumor immune microenvironment in NET/NEC to determine whether checkpoint pathways like programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) might play a role in immune escape and whether other escape mechanisms might need to be targeted to enable a functional antitumor response. Forty-eight NET and thirty NEC samples were analyzed by immunohistochemistry (IHC) and mRNA immunoprofiling including digital spatial profiling. Through IHC, both NET/NEC showed stromal, but less intratumoral CD3+ T cell infiltration, although this was significantly higher in NEC compared to NET. Expression of PD1, PD-L1, and T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) on immune cells was low or nearly absent. mRNA immunoprofiling revealed low expression of IFNγ inducible genes in NET and NEC without any spatial heterogeneity. However, we observed an increased mRNA expression of chemokines, which attract myeloid cells in NET and NEC, and a high abundance of genes related to immunosuppressive myeloid cells and genes with immunosuppressive functions like CD47 and CD74. In conclusion, NET and NEC lack signs of an activation of the adaptive immune system, but rather show abundance of several immunosuppressive genes that represent potential targets for immunomodulation.


  • Open Access

    Comprehensive Assessment of GPR68 Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody

    by Markus Herzig, Pooja Dasgupta, Daniel Kaemmerer, Jörg Sänger, Katja Evert, Stefan Schulz, Amelie Lupp

    GPR68 (OGR1) belongs to the proton-sensing G protein-coupled receptors that are involved in cellular adaptations to pH changes during tumour development. Although expression of GPR68 has been described in many tumour cell lines, little is known about its presence in human tumour entities. We characterised the novel rabbit monoclonal anti-human GPR68 antibody 16H23L16 using various cell lines and tissue specimens. The antibody was then applied to a large series of formalin-fixed, paraffin-embedded normal and neoplastic human tissue samples. Antibody specificity was demonstrated in a Western blot analysis of GPR68-expressing cells using specific siRNAs. Immunocytochemical experiments revealed pH-dependent changes in subcellular localisation of the receptor and internalisation after stimulation with lorazepam. In normal tissue, GPR68 was present in glucagon-producing islet cells, neuroendocrine cells of the intestinal tract, gastric glands, granulocytes, macrophages, muscle layers of arteries and arterioles, and capillaries. GPR68 was also expressed in neuroendocrine tumours, where it may be a positive prognostic factor, in pheochromocytomas, cervical adenocarcinomas, and endometrial cancer, as well as in paragangliomas, medullary thyroid carcinomas, gastrointestinal stromal tumours, and pancreatic adenocarcinomas. Often, tumour capillaries were also strongly GPR68-positive. The novel antibody 16H23L16 will be a valuable tool for basic research and for identifying GPR68-expressing tumours during histopathological examinations.